About Roche Holding AG

Roche is one of the world’s largest pharmaceutical companies, with a market capitalization of approximately CHF 300 billion (USD 380bn). The company operates through two primary divisions:

•Roche Pharmaceuticals: A global leader in biotechnology and the leading provider of treatments for cancer. The division focuses on developing innovative medicines in areas of significant unmet medical need.

•Roche Diagnostics: A world leader in in-vitro diagnostics, providing a wide range of products and services for disease prevention, screening, diagnosis, and monitoring. This includes laboratory automation, digital diagnostics, and software solutions that are integral to modern healthcare.

News

Roche announced its full-year 2025 results on January 29, 2026, demonstrating resilient growth despite significant currency headwinds. The appreciation of the Swiss franc against the US dollar (approximately 12% in 2025) masked the strong underlying performance of the business.

Revenue for the year was 61.52 billion francs vs 60.5 billion francs in 2024, an increase of 1.68%. This increase comes in spite of the weakness of the dollar in 2025. The dollar fell by around 12% against the Swiss franc in 2025, and is down a further 2% to the end of January 2026. Roche said that at constant currencies sales grew 7%.

Growth in operating profit was 5% to CHF 21.8 billion.

Net income attributable to shareholders was 12.88 billion (+51.88%) francs compared to 8.28 billion francs in 2024. EPS increased from 10.31 francs to 16.04 francs (+55.58%). The large increase was mainly due to impairment charges in 2024. Core earnings per share increased by 11% (4% in Swiss francs) to CHF 19.46.

A dividend of 9.80 francs is being proposed, up from 9.70 francs a year ago. Investors in the bearer shares (Symbol RO) will recieve a CHF 0.999 capital reduction payment. Holders of participation certificates (Symbol ROG) will not receive a capital reduction payment. The nominal value of participation certificates (ROG) and the voting bearer certificates (RO) will thus be aligned at CHF 0.001.

Catalysts

The most significant catalyst is the company’s pipeline, which is poised to deliver a new wave of blockbuster drugs:

•CT-388 (Obesity): This drug has the potential to be a multi-billion dollar product. Phase II trials showed an impressive 22.5% placebo-adjusted weight loss, positioning it as a strong competitor to market leaders from Novo Nordisk and Eli Lilly. Phase III trials are commencing in Q1 2026, representing a major near-term milestone.

•Giredestrant (Oncology): An oral breast cancer drug that demonstrated a 30% reduction in disease recurrence or death in Phase III trials. It is expected to become a leading treatment in a market segment that accounts for approximately 70% of all breast cancer cases.

•Fenebrutinib (Neurology): A treatment for multiple sclerosis that has shown unprecedented positive results in Phase III trials, with the potential to become a multi-billion dollar therapy.

With an additional 10 Phase III readouts expected in 2026, there are multiple opportunities for further positive news flow.

Unlike many of its peers, Roche does not face a major patent cliff in the near term. This provides a stable foundation for growth, allowing new product launches to contribute meaningfully to the top line without the pressure of offsetting a steep revenue decline. The company has also demonstrated a strong commitment to shareholder returns, with a proposed dividend increase for the 39th consecutive year.

I believe this company could be a major beneficiary of artificial intelligence and agentic solutions, but so far I am not factoring in any special growth or cost reductions from that.

Risks

•Clinical & Regulatory Risk: The high valuation placed on the pipeline, particularly assets in obesity (CT-388) and Alzheimer's (trontinemab), means that any clinical trial failures or regulatory setbacks could have a material negative impact on the stock.

•Competitive Landscape: The obesity market is highly competitive, with established players like Novo Nordisk and Eli Lilly having a significant head start in manufacturing and commercialization.

•Patent Expiries: While there is no major patent cliff, Roche’s Perjeta (CHF 3.0 billion in sales) and Tecentriq (CHF 3.6 billion in sales) will see patent expiries in 2027, leading to expected biosimilar competition. However, this headwind appears manageable.

Assumptions:

•Free Cash Flow (FCF): I project a base case FCF of CHF 11.5 billion for 2026, which is broadly in line with the 2025 actual of CHF 11.8 billion. I assume a conservative perpetual growth rate of 3.0% thereafter, reflecting the long-term growth potential of the pipeline.

•Discount Rate: I use a range of 5.5% to 7.0% to discount future cash flows, providing a risk-adjusted valuation. N.B. The yield on 30 year Swiss Franc government bonds is 0.40%.

•Earnings Per Share (EPS): Based on management guidance of high-single-digit growth, I forecast an 8% increase in Core EPS for 2026, resulting in a forecast of CHF 21.02.

•P/E Multiple: I apply a P/E multiple range of 18x to 24x to my 2026 EPS forecast, which is in line with the company’s historical valuation and peer group.

Valuation

Based on Discounted Cash Flow:

At 5.5% discount rate: CHF 538 (+53% upside)
At 6.5% discount rate: CHF 379 (+8% upside)
At 7.0% discount rate: CHF 329 (-6% downside)

P/E valuation range (varying multiple):

18x P/E: CHF 378 (+8%)
20x P/E: CHF 420 (+20%)
22x P/E: CHF 462 (+32%)
24x P/E: CHF 504 (+44%)

I will take the average price of the above:

Average Price: CHF 430.00

Current Price: CHF 350.70

Implied Upside: +22.6%

Disclaimer

The user Clive_Thompson has a position in SWX:ROG. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.